The possibilities are endless and URGENT.
Death from MBC is unacceptable.
Research will cure this disease, and until then, research will transform MBC from a terminal diagnosis to a chronic disease, giving patients and their families the priceless gift of time. But time is of the essence. The pandemic we are currently facing has negatively impacted breast cancer research. Lifesaving breast cancer research funding has been diminished and hardworking labs at both Duke and UNC have been impacted. The Komen Metastatic Breast Cancer Collaborative Research Initiative will bring much-needed dollars to these institutions and keep vital research moving forward.
How will it work?
Both the Duke Cancer Institute and the UNC Lineberger Comprehensive Cancer Center are eager to partner with Komen to build on the strong work they are currently doing. There is no doubt that the need for translational research into the understanding, detection, and treatment of metastatic breast cancer is urgent.
This first-of-its-kind fund will ignite innovation and fast-track MBC research. By removing research silos and leveraging local expertise at both institutions, we will accelerate the discovery of ways for MBC patients to live well and live longer with this disease.
$1 Million Milestone
With $1 million secured in commitments, Komen will open the granting process and accept applications. Only collaborative projects between the Duke Cancer Institute and the UNC Lineberger Comprehensive Cancer Center will be eligible. Donate today.
Housed within the highly regarded Komen Research Program, applications will be evaluated through the highly esteemed peer-review process of the Komen Scientific Advisory Board. With this rigorous review and through a true global lens, the fund will drive the most critical research needs for MBC.